In that regard, GLP-1 receptor agonists that are indicated for the treatment of T2DM, also often induce considerable weight loss134,135, which can eliminate obesity-related stigmatization and motivate patients to further work on their metabolic health through lifestyle modifications. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.